Alyglo Market Report 2026

Alyglo Market Overview

• The Alyglo market growth in the historic period has been driven by early ivig adoption in immunodeficiency, plasma fractionation advancements • Market expansion is supported by rising prevalence of immune disorders, improved diagnostic rates • Growth Driver: Rising Prevalence Of Immunodeficiency Diseases Fueling The Alyglo Market Growth • Market Trend: Advancements In Intravenous Immunoglobulin Therapies For Immune System Support • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alyglo Market?

Alyglo is an intravenous immune globulin (IVIG) therapy for treating primary humoral immunodeficiency (PI), which is a condition where the body lacks sufficient antibodies. It contains concentrated human immunoglobulin G (IgG) from pooled plasma and is administered intravenously to enhance immune function by providing vital antibodies. The main types of clinical indications for alyglo are primary humoral immunodeficiency (PI), secondary immunodeficiency, autoimmune disorders, and bone marrow failure syndromes. Primary humoral immunodeficiency (PI) is a disorder where the body lacks sufficient antibodies, increasing susceptibility to infections, and is treated with immune globulin therapies such as Alyglo to restore immunity. It is distributed through several distribution channels, such as hospital pharmacies and specialty pharmacies, and is used by various end-users, including adult, geriatric, and pediatric.

What Is The Alyglo Market Growth Forecast?

The growth in the forecast period can be attributed to rising prevalence of immune disorders, improved diagnostic rates, aging population impact, expansion of home infusion alternatives, strengthened plasma supply networks. Major trends in the forecast period include growing demand for ivig therapies, rising diagnosis of primary immunodeficiency, expansion of hospital-based infusion services, focus on plasma-derived therapy safety, increasing long-term immunoglobulin therapy use.

Global Alyglo Market Segmentation

1) By Clinical Indication: Primary Humoral Immunodeficiency (PI), Secondary Immunodeficiency, Autoimmune Disorders, Bone Marrow Failure Syndromes 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies 3) By End-User: Adult, Geriatric, Pediatric

What Is The Driver Of The Alyglo Market?

The rising prevalence of immunodeficiency diseases is expected to propel the growth of the alyglo market going forward. Immunodeficiency diseases are conditions in which the immune system is weakened or dysfunctional, making it more susceptible to infection. Immunodeficiency diseases are rising due to factors such as increased environmental pollutants, genetic predispositions, better diagnostic capabilities, and the use of immunosuppressive therapies. Alyglo delivers intravenous immunoglobulin (IVIG) therapy to boost the immune system in individuals with primary humoral immunodeficiency (PI) by replenishing deficient antibodies. This treatment helps reduce infections' frequency and severity, improving patients' overall quality of life. For instance, in May 2024, according to the Minnesota Department of Health, a US-based state health agency, in 2023, MDH reported 324 new HIV diagnoses, marking a 24% rise from 2022. Therefore, the rising prevalence of immunodeficiency diseases is driving the growth of the alyglo industry.

Key Players In The Global Alyglo Market

Major companies operating in the alyglo market are GC Biopharma Corp.

Global Alyglo Market Trends and Insights

Major companies operating in the alyglo market are focusing on expanding their treatment portfolios with advanced therapies, such as intravenous immunoglobulins (IGIV), to address complex immune deficiencies, enhance patient care, and improve dosing convenience. Intravenous immunoglobulins refer to antibody-based therapies derived from human plasma, used to treat a variety of immune system disorders by providing functional antibodies to help fight infections. For instance, in November 2024, GC Biopharma USA Inc., a US-based biopharmaceutical company, launched ALYGLO. It is a 10% intravenous immunoglobulin therapy specifically designed for adult patients aged 17 years and older with primary humoral immunodeficiency (PI). Its novel manufacturing process, utilizing cation exchange chromatography (CEX), removes coagulation factor XIa (FXIa) to undetectable levels, enhancing patient safety. The product is FDA-approved and offers a new therapeutic option to improve patient access through a limited distribution network of national specialty pharmacy providers.

What Are Latest Mergers And Acquisitions In The Alyglo Market?

In August 2024, BioCareSD, a US-based specialty distributor for orphan, rare, and ultra-rare diseases, partnered with GC Biopharma. The partnership aims to deliver ALYGLO (immune globulin intravenous) to patients with primary humoral immunodeficiency (PI) through BioCareSD's high-touch service model. This collaboration ensures personalized support and enhances patient outcomes for individuals with rare and complex conditions. GC Biopharma is a South Korea-based pharmaceutical company that manufactures ALYGLO.

Regional Insights

North America was the largest region in the alyglo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Alyglo Market?

The alyglo market consists of sales of immune globulin intravenous (IVIG) liquid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alyglo Market Report 2026?

The alyglo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alyglo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.